Vertex Pharma with clear analyst backing, shares supported by strong consensus estimates
23.06.2026 - 19:05:21 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 17:04.
Vertex Pharma (US92532F1003) sits firmly on the NASDAQ radar with a broad analyst base following the stock. Consensus data now point to a double-digit percentage upside based on 12-month targets from major houses.
What the consensus shows
Across 29 analysts tracked by Investing.com, 27 rate Vertex as Buy, 5 as Hold and 1 as Sell, resulting in a clear Buy consensus for the shares. Investing.com consensus overview The average 12-month price target stands at 548.69 US dollars, with individual targets ranging from 330 to 641 dollars per share. Investing.com price target data
Based on the current spot level around 467 dollars, this average target implies a potential upside of roughly 17 to 18 percent over the coming year, purely on consensus arithmetic. Investing.com upside calculation The 52-week trading range for Vertex shares extends from 362.50 to 507.92 dollars, placing the recent quote in the upper half of that band. Investing.com range data
How the stock trades on NASDAQ
On NASDAQ, Vertex shares recently changed hands around 466 to 468 dollars, following a prior close at 466.79 dollars per share on 22 June 2026 according to MarketBeat and other data providers. MarketBeat VRTX quote and forecast That close was up roughly 3.4 percent on the day, underlining that the stock is not far from the upper end of its 52-week corridor. MarketBeat news and price data
Data from Arincen show a last traded price of 466.77 dollars, a daily gain of 14.98 dollars or 3.32 percent, and a market capitalization near 118.5 billion dollars for Vertex, calculated on that closing level. Arincen VRTX snapshot This positions the company among the larger biotech names alongside peers such as Gilead Sciences and Amgen in the broader US health care sector.
All news and analysis on the Vertex Pharma shares
Further corporate releases, analyst updates and price data on Vertex Pharma can be found in the dedicated topic area and via the company's own Investor Relations pages.
How Vertex earns its money
Vertex Pharma generates the bulk of its revenue from treatments for cystic fibrosis, notably its CFTR modulator therapies such as Trikafta, which target the underlying protein defect in eligible patients. Vertex IR product and revenue breakdown The company is also investing heavily in late-stage programs in sickle cell disease, beta thalassemia and type 1 diabetes, broadening its pipeline beyond cystic fibrosis.
Where the shares trade today
The Vertex Pharma shares (US92532F1003) trade on NASDAQ at 466.77 US dollars as of 2026-06-22, 16:00 Eastern Time.
Vertex Pharma at a glance
- Company: Vertex Pharmaceuticals Incorporated
- ISIN: US92532F1003
- WKN: 882807
- Ticker: VRTX
- Trading venue: NASDAQ
- Price (as of 2026-06-22, 16:00): 466.77 USD
- Market cap: 118,467,993,077 USD (as of 2026-06-22)
- Sector / industry: Health Care / Biotechnology
- Index membership: S&P 500
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. Investors should conduct their own research and consider their individual financial situation before making investment decisions.
